Panacea Life Sciences Holdings annual r&d spending
2014
2015
2016
2017
2018
2019
2020
Panacea Life Sciences Holdings R&D Spending Growth & History (PLSH)
Panacea Life Sciences Holdings's r&d spending was $0 for fiscal 2020.
View full Panacea Life Sciences Holdings company overviewPanacea Life Sciences Holdings annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2020 | 2020-12-31 | $0 | −$22,100 | — |
| 2019 | 2019-12-31 | $22,100 | −$277,900 | −92.63% |
| 2018 | 2018-12-31 | $300,000 | −$56,076 | −15.75% |
| 2017 | 2017-12-31 | $356,076 | −$13,268 | −3.59% |
| 2016 | 2016-12-31 | $369,344 | $292,000 | +377.53% |
| 2015 | 2015-12-31 | $77,344 | $19,024 | +32.62% |
| 2014 | 2014-12-31 | $58,320 | — | — |
Panacea Life Sciences Holdings quarterly r&d spending
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q1.20
Q2.20
Q3.20
Q4.20
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q4 2020 | 2020-12-31 | $0 | — | — |
| Q3 2020 | 2020-09-30 | $0 | −$10,000 | — |
| Q2 2020 | 2020-06-30 | $0 | −$10,000 | — |
| Q1 2020 | 2020-03-31 | $0 | −$15,000 | — |
| Q3 2019 | 2019-09-30 | $10,000 | −$65,000 | −86.67% |
| Q2 2019 | 2019-06-30 | $10,000 | −$65,000 | −86.67% |
| Q1 2019 | 2019-03-31 | $15,000 | −$60,000 | −80.00% |
| Q4 2018 | 2018-12-31 | $75,000 | $0 | 0.00% |
| Q3 2018 | 2018-09-30 | $75,000 | −$12,000 | −13.79% |
| Q2 2018 | 2018-06-30 | $75,000 | −$30,866 | −29.16% |
| Q1 2018 | 2018-03-31 | $75,000 | −$13,210 | −14.98% |
| Q4 2017 | 2017-12-31 | $75,000 | −$77,700 | −50.88% |
| Q3 2017 | 2017-09-30 | $87,000 | −$10,244 | −10.53% |
| Q2 2017 | 2017-06-30 | $105,866 | $13,216 | +14.26% |
| Q1 2017 | 2017-03-31 | $88,210 | $61,460 | +229.76% |
| Q4 2016 | 2016-12-31 | $152,700 | $125,514 | +461.69% |
| Q3 2016 | 2016-09-30 | $97,244 | $72,165 | +287.75% |
| Q2 2016 | 2016-06-30 | $92,650 | $67,571 | +269.43% |
| Q1 2016 | 2016-03-31 | $26,750 | $26,750 | — |
| Q4 2015 | 2015-12-31 | $27,186 | — | — |
| Q3 2015 | 2015-09-30 | $25,079 | — | — |
| Q2 2015 | 2015-06-30 | $25,079 | — | — |
| Q1 2015 | 2015-03-31 | $0 | — | — |
Panacea Life Sciences Holdings r&d spending trends
Over the last five fiscal years, Panacea Life Sciences Holdings's r&d spending decreased from $77,344 to $0, a change of −$77,344. The latest reported quarter, Q4 2020, shows $0.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Panacea Life Sciences Holdings source filings ↗